Inclisiran, sold under the brand name Leqvio, is a medication used for the treatment of high low-density lipoprotein (LDL) cholesterol and for the treatment...

announced that the US Food and Drug Administration (FDA) approved Leqvio (inclisiran), a small interfering RNA (siRNA) therapy to lower low-density lipoprotein...

US and Europe: patisiran (2018), givosiran (2019), lumasiran (2020), inclisiran (2020 in Europe with anticipated US approval in 2021), and vutrisiran...

C10AX13 Evolocumab C10AX14 Alirocumab C10AX15 Bempedoic acid C10AX16 Inclisiran C10AX17 Evinacumab C10AX18 Volanesorsen C10BA01 Lovastatin and nicotinic...

inhibitors are monoclonal antibodies for refractory cases. (e.g. Evolocumab, Inclisiran) They are used in combination with statins. Probucol (withdrawn in several...

hypercholesterolemia, who require additional lowering of LDL cholesterol. More recently Inclisiran has been approved for the treatment of HeFH Although monoclonal antibodies...

PMID 18753623. Santulli G, Jankauskas SS, Gambardella J (May 2021). "Inclisiran: a new milestone on the PCSK9 road to tackle cardiovascular risk". Eur...

order to acquire amongst other assets, the cholesterol lowering therapy; inclisiran. In April 2020, the company announced it would acquire Amblyotech. In...

available for commercial application, and two siRNAs, lumasiran (ALN-GO1) and inclisiran, have been submitted for new drug application to the FDA. Several siRNAs...

1D05-IgG2 (Merck), RG-7652 and LY3015014, as well as the RNAi therapeutic inclisiran. PCSK9 inhibitors are promising therapeutics for the treatment of people...

of the delivery of naked mRNA in vivo. patisiran givosiran lumasiran inclisiran Antisense RNA is the non-coding and single-stranded RNA that is complementary...